DSpace@İnönü

Yazar "Idilman, R" için Araştırma Çıktıları | Pubmed İndeksli Yayınlar Koleksiyonu listeleme

Yazar "Idilman, R" için Araştırma Çıktıları | Pubmed İndeksli Yayınlar Koleksiyonu listeleme

Sırala: Sıra: Sonuçlar:

  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and 
    Idilman, R; Demir, M; Aladag, M; Erol, C; Cavus, B; Iliaz, R; Koklu, H; Cakaloglu, Y; Sahin, M; Ersoz, G; Koksal, I; Karasu, Z; Ozgenel, M; Turan, I; Gunduz, F; Ataseven, H; Akdogan, M; Kiyici, M; Koksal, AS; Akhan, S; Gunsar, F; Tabak, F; Kaymakoglu, S; Akarca, US; Akarsu, M; Alkim, H; Araz, F; Ates, F; Aygen, B; Balik, I; Barut, HS; Baysal, B; Bolat, A; Celik, I; Cosgun, S; Ensaroglu, F; Gokcan, H; Gurel, S; Gursoy, S; Inkaya, AC; Kamilli, C; Kav, T; Kuruuzum, Z; Onder, FO; Ormeci, N; Ozbakir, O; Ozenirler, S; Ozer, B; Ozkan, H; Poturoglu, S; Senates, E; Simsek, H; Toka, B; Unal, H; Yaras, S; Yildirim, AE; Yildirim, B; Yilmaz, B; Yilmaz, H; Yozgat, A; Yurdaydin, C (2019)
    The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease ...
  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and 
    Idilman, R; Demir, M; Aladag, M; Erol, C; Cavus, B; Iliaz, R; Koklu, H; Cakaloglu, Y; Sahin, M; Ersoz, G; Koksal, I; Karasu, Z; Ozgenel, M; Turan, I; Gunduz, F; Ataseven, H; Akdogan, M; Kiyici, M; Koksal, AS; Akhan, S; Gunsar, F; Tabak, F; Kaymakoglu, S; Akarca, US; Akarsu, M; Alkim, H; Araz, F; Ates, F; Aygen, B; Balik, I; Barut, HS; Baysal, B; Bolat, A; Celik, I; Cosgun, S; Ensaroglu, F; Gokcan, H; Gurel, S; Gursoy, S; Inkaya, AC; Kamilli, C; Kav, T; Kuruuzum, Z; Onder, FO; Ormeci, N; Ozbakir, O; Ozenirler, S; Ozer, B; Ozkan, H; Poturoglu, S; Senates, E; Simsek, H; Toka, B; Unal, H; Yaras, S; Yildirim, AE; Yildirim, B; Yilmaz, B; Yilmaz, H; Yozgat, A; Yurdaydin, C (2019)
    The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease ...
  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and 
    Idilman, R; Demir, M; Aladag, M; Erol, C; Cavus, B; Iliaz, R; Koklu, H; Cakaloglu, Y; Sahin, M; Ersoz, G; Koksal, I; Karasu, Z; Ozgenel, M; Turan, I; Gunduz, F; Ataseven, H; Akdogan, M; Kiyici, M; Koksal, AS; Akhan, S; Gunsar, F; Tabak, F; Kaymakoglu, S; Akarca, US; Akarsu, M; Alkim, H; Araz, F; Ates, F; Aygen, B; Balik, I; Barut, HS; Baysal, B; Bolat, A; Celik, I; Cosgun, S; Ensaroglu, F; Gokcan, H; Gurel, S; Gursoy, S; Inkaya, AC; Kamilli, C; Kav, T; Kuruuzum, Z; Onder, FO; Ormeci, N; Ozbakir, O; Ozenirler, S; Ozer, B; Ozkan, H; Poturoglu, S; Senates, E; Simsek, H; Toka, B; Unal, H; Yaras, S; Yildirim, AE; Yildirim, B; Yilmaz, B; Yilmaz, H; Yozgat, A; Yurdaydin, C (2019)
    The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease ...
  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and 
    Idilman, R; Demir, M; Aladag, M; Erol, C; Cavus, B; Iliaz, R; Koklu, H; Cakaloglu, Y; Sahin, M; Ersoz, G; Koksal, I; Karasu, Z; Ozgenel, M; Turan, I; Gunduz, F; Ataseven, H; Akdogan, M; Kiyici, M; Koksal, AS; Akhan, S; Gunsar, F; Tabak, F; Kaymakoglu, S; Akarca, US; Akarsu, M; Alkim, H; Araz, F; Ates, F; Aygen, B; Balik, I; Barut, HS; Baysal, B; Bolat, A; Celik, I; Cosgun, S; Ensaroglu, F; Gokcan, H; Gurel, S; Gursoy, S; Inkaya, AC; Kamilli, C; Kav, T; Kuruuzum, Z; Onder, FO; Ormeci, N; Ozbakir, O; Ozenirler, S; Ozer, B; Ozkan, H; Poturoglu, S; Senates, E; Simsek, H; Toka, B; Unal, H; Yaras, S; Yildirim, AE; Yildirim, B; Yilmaz, B; Yilmaz, H; Yozgat, A; Yurdaydin, C (2019)
    The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease ...
  • Real-world efficacy and safety of Ledipasvir plus Sofosbuvir and 
    Degertekin, B; Demir, M; Akarca, US; Kani, HT; Ucbilek, E; Yildirim, E; Guzelbulut, F; Balkan, A; Vatansever, S; Danis, N; Demircan, M; Soylu, A; Yaras, S; Kartal, A; Kefeli, A; Gunduz, F; Yalcin, K; Erarslan, E; Aladag, M; Harputluoglu, M; Ozakyol, A; Temel, T; Akarsu, M; Sumer, H; Akin, M; Albayrak, B; Sen, I; Alkim, H; Uyanikoglu, A; Irak, K; Oztaskin, S; Ugurlu, CB; Gunes, S; Gurel, S; Nuriyev, K; Inci, I; Kacar, S; Dincer, D; Doganay, L; Gokturk, HS; Mert, A; Cosar, AM; Dursun, H; Atalay, R; Akbulut, S; Balkan, Y; Koklu, H; Simsek, H; Ozdogan, O; Coban, M; Poturoglu, S; Ayyildiz, T; Yapali, S; Gunsar, F; Akdogan, M; Ozenirler, S; Akyildiz, M; Sezgin, O; Kaymakoglu, S; Besisik, F; Karasu, Z; Idilman, R (2020)
    Background/Aims: This study aimed to evaluate the real-life efficacy and tolerability of direct-acting antiviral treatments for patients with chronic hepatitis C (CHC) with/without cirrhosis in the Turkish population.
  • Real-world efficacy and safety of Ledipasvir plus Sofosbuvir and 
    Degertekin, B; Demir, M; Akarca, US; Kani, HT; Ucbilek, E; Yildirim, E; Guzelbulut, F; Balkan, A; Vatansever, S; Danis, N; Demircan, M; Soylu, A; Yaras, S; Kartal, A; Kefeli, A; Gunduz, F; Yalcin, K; Erarslan, E; Aladag, M; Harputluoglu, M; Ozakyol, A; Temel, T; Akarsu, M; Sumer, H; Akin, M; Albayrak, B; Sen, I; Alkim, H; Uyanikoglu, A; Irak, K; Oztaskin, S; Ugurlu, CB; Gunes, S; Gurel, S; Nuriyev, K; Inci, I; Kacar, S; Dincer, D; Doganay, L; Gokturk, HS; Mert, A; Cosar, AM; Dursun, H; Atalay, R; Akbulut, S; Balkan, Y; Koklu, H; Simsek, H; Ozdogan, O; Coban, M; Poturoglu, S; Ayyildiz, T; Yapali, S; Gunsar, F; Akdogan, M; Ozenirler, S; Akyildiz, M; Sezgin, O; Kaymakoglu, S; Besisik, F; Karasu, Z; Idilman, R (2020)
    Background/Aims: This study aimed to evaluate the real-life efficacy and tolerability of direct-acting antiviral treatments for patients with chronic hepatitis C (CHC) with/without cirrhosis in the Turkish population.
  • Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An 
    Efe, C; Dhanasekaran, R; Lammert, C; Ebik, B; Higuera-de la Tijera, F; Aloman, C; Caliskan, AR; Peralta, M; Gerussi, A; Massoumi, H; Catana, AM; Torgutalp, M; Purnak, T; Rigamonti, C; Aldana, AJG; Khakoo, N; Kacmaz, H; Nazal, L; Frager, S; Demir, N; Irak, K; Ellik, ZM; Balaban, Y; Atay, K; Eren, F; Cristoferi, L; Batibay, E; Urzua, A; Snijders, R; Kiyici, M; Akyildiz, M; Ekin, N; Carr, RM; Harputluoglu, M; Hatemi, I; Mendizabal, M; Silva, M; Idilman, R; Silveira, M; Drenth, JPH; Assis, DN; Bjornsson, E; Boyer, JL; Invernizzi, P; Levy, C; Schiano, TD; Ridruejo, E; Wahlin, S (2021)
    Background and Aims Data regarding outcome of COVID-19 in patients with autoimmune hepatitis (AIH) are lacking.
  • Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis 
    Akarsu, M; Onem, S; Turan, I; Adali, G; Akdogan, M; Akyildiz, M; Aladag, M; Balaban, Y; Danis, N; Dayangac, M; Gencdal, G; Gokcan, H; Sertesen, E; Gurakar, M; Harputluoglu, M; Kabacam, G; Karademir, S; Kiyici, M; Idilman, R; Karasu, Z (2021)
    The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended ...
  • Effects of immunosuppressive drugs on COVID-19 severity in patients with 
    Efe, C; Lammert, C; Tascilar, K; Dhanasekaran, R; Ebik, B; Higuera-de la Tijera, F; Caliskan, AR; Peralta, M; Gerussi, A; Massoumi, H; Catana, AM; Purnak, T; Rigamonti, C; Aldana, AJG; Khakoo, N; Nazal, L; Frager, S; Demir, N; Irak, K; Melekoglu-Ellik, Z; Kacmaz, H; Balaban, Y; Atay, K; Eren, F; Alvares-da-Silva, MR; Cristoferi, L; Urzua, A; Eskazan, T; Magro, B; Snijders, R; Barutcu, S; Lytvyak, E; Zazueta, GM; Demirezer-Bolat, A; Aydin, M; Heurgue-Berlot, A; De Martin, E; Ekin, N; Yildirim, S; Yavuz, A; Biyik, M; Narro, GC; Kiyici, M; Akyildiz, M; Kahramanoglu-Aksoy, E; Vincent, M; Carr, RM; Gunsar, F; Reyes, EC; Harputluoglu, M; Aloman, C; Gatselis, NK; Ustundag, Y; Brahm, J; Vargas, NCE; Guzelbulut, F; Garcia, SR; Aguirre, J; Anders, M; Ratusnu, N; Hatemi, I; Mendizabal, M; Floreani, A; Fagiuoli, S; Silva, M; Idilman, R; Satapathy, SK; Silveira, M; Drenth, JPH; Dalekos, GN; Assis, DN; Bjornsson, E; Boyer, JL; Yoshida, EM; Invernizzi, P; Levy, C; Montano-Loza, AJ; Schiano, TD; Ridruejo, E; Wahlin, S (2022)
    Background We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods Data of AIH patients with ...
  • Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated 
    Efe, C; Kulkarni, AV; Beretta-Piccoli, BT; Magro, B; Stattermayer, AF; Cengiz, M; Clayton-Chubb, D; Lammert, C; Bernsmeier, C; Gul, O; Higuera-de la Tijera, FH; Anders, M; Lytvyak, E; Akin, M; Purnak, T; Liberal, R; Peralta, M; Ebik, B; Duman, S; Demir, N; Balaban, Y; Urzua, A; Contreras, F; Venturelli, MG; Bilgic, Y; Medina, A; Girala, M; Gunsar, F; Londono, MC; Androutsakos, T; Kisch, A; Yurci, A; Guzelbult, F; Cagin, YF; Avci, E; Guzelbulut, M; Dindar-Demiray, EK; Harputluoglu, M; Kumar, R; Satapathy, SK; Mendizabal, M; Silva, M; Fagiuoli, S; Roberts, SK; Soylu, NK; Idilman, R; Yoshida, EM; Montano-Loza, AJ; Dalekos, GN; Ridruejo, E; Schiano, TD; Wahlin, S
    Background and Aims A few case reports of autoimmune hepatitis-like liver injury have been reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We evaluated clinical features, treatment ...